Anika Therapeutics/ANIK

$24.77

-1.93%
-
1D1W1MYTD1YMAX

About Anika Therapeutics

Anika Therapeutics, Inc. is a joint preservation company. The Company is engaged in creating and delivering advancements in early intervention orthopedic care, including osteoarthritis (OA) pain management, regenerative solutions, sports medicine and Arthrosurface joint solutions. The Company is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product line includes OA Pain Management, Joint Preservation and Restoration, and Non-Orthopedic. Its OA Pain Management product consists of Monovisc and Orthovisc, Cingal, and Hyvisc. Its Joint Preservation and Restoration consist of regenerative solutions, sports medicine, and Arthrosurface joint solutions. Monovisc and Orthovisc are single and multi-injection, HA-based Visco supplement products, Cingal, and Hyvis. Its Non-Orthopedic products consists of HA-based products that are marketed principally for non-orthopedic applications.

Ticker

ANIK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Cheryl Blanchard

Employees

345

Headquarters

Bedford, United States
Website
anika.com

ANIK Metrics

BasicAdvanced
$371.88M
Market cap
-
P/E ratio
-$1.68
EPS
0.76
Beta
-
Dividend rate

What the Analysts think about ANIK

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
11.71% upside
High $32.00
Low $22.00
$24.77
Current price
$27.67
Average price target

ANIK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-15.7% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$41.4M
-6.55%
Net income
$-6.5M
140.74%
Profit margin
-15.7%
157.8%

ANIK Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 20.54%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.34
-$0.71
-$0.19
-$0.45
-
Expected
-$0.24
-$0.30
-$0.27
-$0.37
-$0.26
Surprise
41.67%
136.67%
-29.63%
20.54%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Anika Therapeutics stock

Buy or sell Anika Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing